Metformin treatment to reduce central adiposity after prenatal growth restraint: A placebo-controlled pilot study in prepubertal children

Pediatric Diabetes

Volumn 16, Issue 7, 2015, Pages 538-545

  Díaz, Marta ^a,b   Bassols, Judit ^c   López Bermejo, Abel ^c   de Zegher, Francis ^d   Ibáñez, Lourdes ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adipose tissue; Body composition; Catch up; IGF I; Insulin; Metformin; Small for gestational age; Visceral fat

Indexed keywords

ADIPONECTIN; ANDROGEN; GLUCOSE; INSULIN; LIPID; METFORMIN; PLACEBO; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BIOLOGICAL MARKER;

ABDOMINAL FAT; ABSORPTIOMETRY; ANTHROPOMETRY; ARTERIAL WALL THICKNESS; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CENTRAL OBESITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ECHOGRAPHY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PILOT STUDY; PRENATAL GROWTH; PREPUBERTY; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SMALL FOR DATE INFANT; WAIST CIRCUMFERENCE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; FETAL GROWTH RETARDATION; METABOLISM; MULTICENTER STUDY; OBESITY, ABDOMINAL; PATHOLOGY; PATHOPHYSIOLOGY; PEDIATRIC OBESITY; RANDOMIZED CONTROLLED TRIAL;

ABDOMINAL FAT; ADIPOSITY; ANTI-OBESITY AGENTS; BIOMARKERS; BODY MASS INDEX; CHILD; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FETAL GROWTH RETARDATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LONGITUDINAL STUDIES; MALE; METFORMIN; OBESITY, ABDOMINAL; PEDIATRIC OBESITY; PILOT PROJECTS; WAIST CIRCUMFERENCE;

EID: 84942903902     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12220     Document Type: Article

References (40)

1. Bhargava SK, Sachdev HS, Fall CH et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004: 350: 865-875.
2. Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG. Trajectories of growth among children who have coronary events as adults. N Engl J Med 2005: 353: 1802-1809.
3. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL. Children born small for gestational age: do they catch up? Pediatr Res 1995: 38: 267-271.
4. Taal HR, Vd Heijden AJ, Steegers EA, Hofman A, Jaddoe VW. Small and large size for gestational age at birth, infant growth, and childhood overweight. Obesity (Silver Spring) 2013: 21: 1261-1268.
5. Ibáñez L, Ong K, Dunger DB, de Zegher F. Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. J Clin Endocrinol Metab 2006: 91: 2153-2158.
6. Ibáñez L, Suarez L, López-Bermejo A, Díaz M, Valls C, de Zegher F. Early development of visceral fat excess after spontaneous catch-up growth in children with low birth weight. J Clin Endocrinol Metab 2008: 93: 925-928.
7. Ibáñez L, López-Bermejo A, Suarez L, Marcos MV, Díaz M, de Zegher F. Visceral adiposity without overweight in children born small for gestational age. J Clin Endocrinol Metab 2008: 93: 2079-2083.
8. Ong KK, Potau N, Petry CJ et al. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004: 89: 2647-2651.
9. Ibáñez L, López-Bermejo A, Díaz M, Suárez L, de Zegher F. Low-birth weight children develop lower sex hormone binding globulin and higher dehydroepiandrosterone sulfate levels and aggravate their visceral adiposity and hypoadiponectinemia between six and eight years of age. J Clin Endocrinol Metab 2009: 94: 3696-3699.
10. Ibáñez L, Jimenez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics 2006: 117: 117-121.
11. Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 2006: 91: 2888-2891.
12. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity. J Pediatr 2010: 156: e10198-e101102.
13. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil Steril 2011: 95: 727-730.
14. Ferrández-Longas A, Mayayo E, Labarta JI et al. Estudio longitudinal de crecimiento y desarrollo. Centro Andrea Prader. Zaragoza 1980-2002. In: Garcia-Dihinx A, Romo A, Ferrandez-Longas A, eds. Patrones de crecimiento y desarrollo en España. Madrid: Ergon, 2004: 61-115.
15. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007: 92: 804-810.
16. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969: 44: 291-303.
17. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970: 45: 13-23.
18. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998: 21: 2191-2192.
19. Osiniri I, Sitjar C, Soriano-Rodriguez P et al. Carotid intima-media thickness at 7 years of age: relationship to C-reactive protein rather than adiposity. J Pediatr 2012: 160: e271276-e271280.
20. Wells JC, Cole TJ. Adjustment of fat-free mass and fat mass for height in children aged 8 y. Int J Obes Relat Metab Disord 2002: 26: 947-952.
21. Zhang J, Himes JH, Guo Y et al. Birth weight, growth and feeding pattern in early infancy predict overweight/obesity status at two years of age: a birth cohort study of Chinese infants. PLoS One 2013: 8: e64542.
22. Skilton MR, Marks GB, Ayer JG et al. Weight gain in infancy and vascular risk factors in later childhood. Pediatrics 2013: 131: e1821-e1828.
23. Reinehr T, Kleber M, Toschke AM. Small for gestational age status is associated with metabolic syndrome in overweight children. Eur J Endocrinol 2009: 160: 579-584.
24. Szalapska M, Stawerska R, Borowiec M, Mlynarski W, Lewinski A, Hilczer M. Metabolic syndrome components among children born small for gestational age: analysis of the first decade of life. Pediatr Endocrinol Diabetes Metab 2010: 16: 270-276.
25. Kong AP, Choi KC, Wong GW et al. Serum concentrations of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and cardiovascular risk factors in adolescents. Ann Clin Biochem 2011: 48: 263-269.
26. Katzmarzyk PT, Heymsfield SB, Bouchard C. Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults. Am J Clin Nutr 2013: 97: 480-486.
27. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001: 107: E55.
28. TODAY Study Group. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. Diabetes Care 2013: 36: 1765-1771.
29. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr 2014: 168: 178-184.
30. Dervaux N, Wubuli M, Megnien JL, Chironi G, Simon A. Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects. Atherosclerosis 2008: 201: 413-417.
31. Harrington DM, Staiano AE, Broyles ST, Gupta AK, Katzmarzyk PT. Waist circumference measurement site does not affect relationships with visceral adiposity and cardiometabolic risk factors in children. Pediatr Obes 2013: 8: 199-206.
32. Rodriguez-Moctezuma JR, Robles-Lopez G, Lopez-Carmona JM, Gutierrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab 2005: 7: 189-192.
33. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001: 108: 1167-1174.
34. Hoffman RP. Indices of insulin action calculated from fasting glucose and insulin reflect hepatic, not peripheral, insulin sensitivity in African-American and Caucasian adolescents. Pediatr Diabetes 2008: 9: 57-61.
35. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013: 36: 1758-1764.
36. Preiss D, Lloyd SM, Ford I et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2014: 2: 116-124.
37. Calderon-Margalit R, Schwartz SM, Wellons MF et al. Prospective association of serum androgens and sex hormone-binding globulin with subclinical cardiovascular disease in young adult women: the Coronary Artery Risk Development in Young Adults women's study. J Clin Endocrinol Metab 2010: 95: 4424-4431.
38. Canoy D, Barber TM, Pouta A et al. Serum sex hormone-binding globulin and testosterone in relation to cardiovascular disease risk factors in young men: a population-based study. Eur J Endocrinol 2014[Epub ahead of print].
39. Sørensen K, Aksglaede L, Munch-Andersen T et al. Sex hormone-binding globulin levels predict insulin sensitivity, disposition index, and cardiovascular risk during puberty. Diabetes Care 2009: 32: 909-914.
40. Ibáñez L, Valls C, Ong K, Dunger DB, de Zegher F. Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab 2006: 91: 2068-2073.